BioSpace News Archive

Clinical and preclinical studies demonstrate ibrexafungerp’s broad-spectrum activity and potential to treat a range of serious and life-threatening fungal infections

- Financing led by GV with participation from Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management, and SoftBank Vision Fund 2 - ETX101, Encoded’s lead asset, was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by FDA for the treatment of SCN1A+ Dravet Syndrome - Encoded plans to initiate ENVISION, an observati

Environmental Diagnostics Laboratory (EDLab) at Pure Air Control Services was awarded accreditation from A2LA on June 10, 2020 for the testing environmental SARS-CoV-2 (coronavirus).

Q BioMed continues its collaboration with Chemveda Life Sciences to prepare for pre-clinical evaluation, Orphan Drug filing and Investigational New Drug (IND) filing of Uttroside-B Novel Therapeutic Shows Remarkable Efficacy in HepG2 Cell Lines NEW YORK , July 22, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences are very pleased to contin

Nexelis, a portfolio company of Ampersand Capital Partners and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, is pleased to announce its acquisition of AIT Bioscience.

OSSIO Announces U.S. Launch and First Commercial Use of the OSSIO fiber ® Trimmable Fixation Nail System for Broad Utilization in Foot/Ankle and Hand/Wrist Procedures New Biointegrative System Offers Screw-Like Stability with the Utility of a Trimmable Nail, Leaving No Permanent Implant Behind WOBURN, Mass.--( BUSINESS WIRE )-- OSSIO, Inc., an orthopedic fixation company, today announced the U.S. launch and first commercial use of the OSSIO fiber ® Tr

Talaris Therapeutics, Inc. , a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced that the first patient has been dosed in the FREEDOM-1 Phase 3 clinical trial of FCR001 in living donor kid

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its infectious disease product line with the addition of 16 new synthetic controls for the environmental testing, assay development, verific

Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the quarter and year ended April 30, 2020, on Monday,

Eko today announced that it has been awarded a $2.7 million Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH).